Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-795-6558
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.91 million
Profitability
Miscellaneous
Employees113
OptionableOptionable
Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therapeutics' stock symbol?
Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."
How were Obalon Therapeutics' earnings last quarter?
Obalon Therapeutics Inc (NASDAQ:OBLN) announced its earnings results on Thursday, August, 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.06. The firm earned $2.73 million during the quarter, compared to analyst estimates of $3.40 million. Obalon Therapeutics had a negative net margin of 178.84% and a negative return on equity of 80.38%. View Obalon Therapeutics' Earnings History.
When is Obalon Therapeutics' next earnings date?
What guidance has Obalon Therapeutics issued on next quarter's earnings?
Obalon Therapeutics updated its FY 2018 earnings guidance on Thursday, January, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $9-9.9 million, compared to the consensus revenue estimate of $9.37 million.
What price target have analysts set for OBLN?
5 brokers have issued 1-year price targets for Obalon Therapeutics' shares. Their forecasts range from $2.00 to $10.00. On average, they anticipate Obalon Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 141.5% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.
What is the consensus analysts' recommendation for Obalon Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obalon Therapeutics.
What are Wall Street analysts saying about Obalon Therapeutics stock?
Here are some recent quotes from research analysts about Obalon Therapeutics stock:
- 1. Northland Securities analysts commented, "We are tweaking our models to reflect our best interpretation" of company commentary. FY19 guidance will be provided on the Q4 call sometime in February. Overall, our fundamental concerns on the story remain." (1/3/2019)
- 2. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (11/14/2018)
- 3. BTIG Research analysts commented, "2Q18 results came in light. Though reordering trends were strong in the quarter (+220% sequentially), new accounts sold came in below our expectations. As the company remains in the early innings of its commercial ramp, it appears this quarter that there continues to be refinement of the sales pitch and go-to-market strategy. Going forward, much of the sales focus will be on more productive accounts with OBLN establishing new clinical programs to assist with imaging acquisition – the biggest barrier to initial uptake. We trim our FY18 revenue estimates once again as we think it will take more time for some of these initiatives to bear fruit. In thinking about shares, we think the upcoming investor call (perhaps early September) to more explicitly discuss the marketing strategy and/or PMA approval of the Navigator system in 1H19 may lift sentiment." (8/5/2018)
Has Obalon Therapeutics been receiving favorable news coverage?
Press coverage about OBLN stock has been trending positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Obalon Therapeutics earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of Obalon Therapeutics' key competitors?
Some companies that are related to Obalon Therapeutics include T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), iCAD (ICAD), RA Medical Systems (RMED), Apollo Endosurgery (APEN), Invo Bioscience (IVOB), CAS Medical Systems (CASM), Motus GI (MOTS), Arch Therapeutics (ARTH), Pro-Dex (PDEX), Alphatec (ATEC), Titan Medical (TMDI) and Endologix (ELGX).
Who are Obalon Therapeutics' key executives?
Obalon Therapeutics' management team includes the folowing people:
- Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
- Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
- Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
- Mr. Mark C. Brister, Chief Technology Officer (Age 57)
- Mr. Todd Michael Wood, VP of Global Sales
When did Obalon Therapeutics IPO?
(OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.
Who are Obalon Therapeutics' major shareholders?
Obalon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Hoylecohen LLC (0.45%), Geode Capital Management LLC (0.28%), BlackRock Inc. (0.14%) and Bank of New York Mellon Corp (0.06%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar, Neil Drake, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.
Which institutional investors are selling Obalon Therapeutics stock?
Which institutional investors are buying Obalon Therapeutics stock?
OBLN stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Bank of New York Mellon Corp and BlackRock Inc.. Company insiders that have bought Obalon Therapeutics stock in the last two years include Kim P Kamdar, Neil Drake, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.
How do I buy shares of Obalon Therapeutics?
Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obalon Therapeutics' stock price today?
One share of OBLN stock can currently be purchased for approximately $2.07.
How big of a company is Obalon Therapeutics?
Obalon Therapeutics has a market capitalization of $48.67 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.
What is Obalon Therapeutics' official website?
How can I contact Obalon Therapeutics?
Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]
MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
